Want to see BCAB full AI Analyst Report?
BCAB Stock Chart & Stats
$0.19
-$0.03(-5.55%)
At close: 4:00 PM EST
$0.19
-$0.03(-5.55%)
Day’s Range― - ―
52-Week Range$3.12 - $71.50
Previous CloseN/A
Volume775.41K
Average Volume (3M)59.87K
Market Cap
$6.62M
Enterprise Value$16.22
Total Cash (Recent Filing)$1.96M
Total Debt (Recent Filing)$6.09M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.72
Shares Outstanding1,659,554
10 Day Avg. Volume59,234
30 Day Avg. Volume59,874
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Differentiation (CAB)BioAtla's CAB platform is a structural competitive advantage: tumor‑selective activation can improve therapeutic index and lower safety attrition. Over months this enhances asset attractiveness to partners and reduces clinical failure risk, supporting durable licensing and collaboration value.
Focused Clinical PipelineA clinical-stage pipeline focused on solid tumors and targets like AXL creates multiple development paths. Multiple assets raise the likelihood of a positive clinical or regulatory event, underpinning sustained partnering opportunities and long‑term upside beyond any single program.
Low Nominal Debt BurdenAbsolute debt is modest, limiting near‑term interest and covenant strain. Lower nominal leverage reduces refinancing urgency, giving management flexibility to pursue staged financings or partnerships to fund trials and preserving operational continuity over the medium term.
Bears Say
Persistent Cash BurnHeavy, ongoing cash outflows create a structural funding requirement: without durable product revenue, the company must repeatedly access external capital or milestones. This raises dilution risk, forces program prioritization, and constrains the pace of clinical development in the coming months.
Minimal And Declining RevenueVery low and falling revenue means the business lacks internal recurring income to fund R&D. This weak revenue base amplifies dependence on financing or partner milestones, reduces resilience to setbacks, and limits ability to scale operations or retain optionality across programs.
Negative Equity & Shrinking AssetsNegative shareholders' equity and a materially reduced asset base materially weaken financial flexibility. This structural deterioration limits borrowing capacity, can deter counterparties, and increases the likelihood of dilutive financings or constrained partnership terms over the medium term.
BioAtla News
BCAB FAQ
What was Bioatla, Inc.’s price range in the past 12 months?
Bioatla, Inc. lowest stock price was $3.12 and its highest was $71.50 in the past 12 months.
What is Bioatla, Inc.’s market cap?
Bioatla, Inc.’s market cap is $6.62M.
When is Bioatla, Inc.’s upcoming earnings report date?
Bioatla, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 18 days.
How were Bioatla, Inc.’s earnings last quarter?
Currently, no data Available
Is Bioatla, Inc. overvalued?
According to Wall Street analysts Bioatla, Inc.’s price is currently Overvalued.
Does Bioatla, Inc. pay dividends?
Bioatla, Inc. does not currently pay dividends.
What is Bioatla, Inc.’s EPS estimate?
Bioatla, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioatla, Inc. have?
Bioatla, Inc. has 1,659,554 shares outstanding.
What happened to Bioatla, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bioatla, Inc.?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioatla, Inc.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
27.13% Insiders
11.81% Mutual Funds
― Other Institutional Investors
59.51% Public Companies and
Individual Investors